Bausch & Lomb CORP 8-K filings

Bausch + Lomb Corporation announces amendments to its prior 8-K filing, detailing significant shifts in Board leadership and committee appointments effective August 5th and August 10th, 2026.

Bausch + Lomb Corporation announced updates to its Board of Directors and reaffirmed its full-year 2026 financial guidance, following a strong second quarter with 9% revenue growth.

Bausch + Lomb Corporation announced robust second-quarter 2026 results, with revenue up 9% and full-year guidance increased.

Bausch + Lomb Corporation shareholders re-elected all director nominees and approved executive compensation at the Annual Meeting on May 20, 2026, also appointing PricewaterhouseCoopers LLP as auditor.

Bausch + Lomb Corporation reported strong first-quarter 2026 results, with revenue up 9% and a significant improvement in operating income, leading to a raised full-year guidance.

Bausch + Lomb Corporation has successfully refinanced its outstanding Term B loans, securing a new $2.8 billion tranche with reduced interest margins and an extended maturity for a portion of its debt.

Bausch + Lomb Corporation announced the appointment of recently added directors, Dr. Eduardo C. Alfonso and Steven H. Collis, to key board committees, effective January 1, 2026.

Bausch + Lomb Corporation announced the appointment of Dr. Eduardo C. Alfonso and Steven H. Collis to its board of directors, effective January 1, 2026.

Bausch + Lomb announced a $2.8 billion refinancing of its outstanding Term B loans, securing lower interest rates and extending maturity for a portion of the debt.

Bausch + Lomb outlined a comprehensive three-year strategy at its Investor Day, targeting above-market revenue growth, significant margin expansion, and a robust product pipeline with $7 billion in potential peak sales.

Bausch + Lomb Corporation announced third-quarter 2025 financial results, reporting broad-based revenue growth and an updated, higher full-year Adjusted EBITDA guidance.

Bausch + Lomb announces the resignation of two directors appointed by the Icahn Group following the termination of their director appointment agreement.

Bausch + Lomb Corporation reported second-quarter 2025 revenue of $1.278 billion, a 5% increase, and raised its full-year 2025 financial guidance, reflecting solid business performance and foreign exchange impacts, even as it posted a GAAP net loss.

Bausch + Lomb Corporation has amended CEO Brenton L. Saunders' employment agreement and performance stock unit award, tying a significant portion of his compensation to long-term share price and Adjusted EBITDA targets through 2029.

Bausch + Lomb announced the successful closing of a €675 million senior secured notes offering and a partial credit agreement refinancing, including a new $2.325 billion term loan and an $800 million revolving credit facility, aimed at repaying existing debt and enhancing financial flexibility.

Bausch + Lomb Corporation announced the pricing of an upsized $675 million senior secured floating rate notes offering and an increased $2.325 billion new term B loan facility, intended to refinance existing debt and enhance financial flexibility.

Bausch + Lomb Corporation announced a significant financial restructuring initiative, including a $600 million senior secured notes offering and a partial refinancing of its credit agreement with new term B and revolving credit facilities totaling $3 billion, aimed at repaying existing debt.

Bausch + Lomb Corporation held its Annual Meeting of Shareholders on May 21, 2025, where shareholders elected directors, approved executive compensation, and appointed PricewaterhouseCoopers LLP as the auditor.

Bausch + Lomb's majority shareholder, Bausch Health Companies Inc., has entered into agreements with key shareholder groups to manage their influence and voting rights.

Bausch + Lomb announced its first-quarter 2025 financial results, including revenue growth of 3% (5% on a constant currency basis) and an update to its full-year guidance to reflect the impact of the enVista IOL voluntary recall.

Bausch + Lomb announced a 9% revenue increase for Q4 2024 and a 16% increase for the full year, driven by growth across all segments and providing a positive outlook for 2025.

Bausch + Lomb Corporation has entered into an agreement for $400 million in new term loans, primarily to repay existing revolving loans and for general corporate purposes.

Bausch + Lomb announced a 19% revenue increase in Q3 2024, driven by growth across all segments, and raised its full-year revenue guidance.

Bausch + Lomb announced a 17% revenue increase in Q2 2024, driven by growth across all business segments, and raised its full-year revenue and adjusted EBITDA guidance.

Bausch + Lomb shareholders approved an increase in common shares authorized for issuance under the 2022 Omnibus Incentive Plan and elected ten directors at their annual meeting on May 29, 2024.

Bausch + Lomb announced impressive first-quarter 2024 results, with revenue growth of 18% as reported and 20% on a constant currency basis, leading to an increase in full-year revenue guidance.

Bausch + Lomb has appointed Karen Ling to its Board of Directors, while Richard De Schutter will retire following the 2024 Annual Meeting of Shareholders.

Bausch + Lomb exceeded expectations with double-digit revenue growth in Q4 and full-year 2023, driven by strong performance across all segments and strategic acquisitions.